..

எய்ட்ஸ் & மருத்துவ ஆராய்ச்சி இதழ்

ஐ.எஸ்.எஸ்.என்: 2155-6113

திறந்த அணுகல்
கையெழுத்துப் பிரதியை சமர்ப்பிக்கவும் arrow_forward arrow_forward ..

Drug Resistance Patterns and Virus Re-Suppression among HIV-1 Subtype C Infected Patients Receiving Non-Nucleoside Reverse Transcriptase Inhibitors in South Africa

Abstract

Ziad El-Khatib, Allison K. DeLong, David Katzenstein, Anna Mia Ekstrom, Johanna Ledwaba, Lerato Mohapi, Fatima Laher, Max Petzold, Lynn Morris and Rami Kantor

Background: Emergence of HIV-1 drug resistance is at times an inevitable and anticipated consequence of antiretroviral therapy (ART) failure. We examined drug resistance patterns and virus re-suppression among subtype C-infected South African patients receiving first-line ART. Methods: Treatment records of 431 patients on NNRTI-containing regimens for a median of 45 months were analyzed. Patients with viral load (VL) >400 copies/mL were followed and drug resistance mutations (DRM) were re-assessed. Associations between clinical/demographic measures and drug resistance/virologic outcomes were examined using Fisher exact and ordinal and logistic regression. Results: Ten percent of patients (43/431) were viremic at enrollment (98%) sequences were obtained from 38/43. Of those, 82% had 1-7 DRM. In bivariate analysis remote exposure to single-dose nevirapine or prior ART; higher CD4 counts; lower VL; and >6 months of virologic failure were significantly associated with number of DRM. Of 25 viremic patients followed for a median of 8 months on a continued first-line regimen, 12 (48%) re-suppressed, six with K103N and three with M184V. Thirteen (52%) had continued virologic failure which was significantly associated with detectable VL >6 months prior to enrollment and number of DRM. Conclusion: Among these HIV-1 subtype C-infected patients, DRM numbers and patterns were associated with prior exposure to sub-optimal ART, adherence and duration of virologic failure. Viral re-suppression in the presence of K103N and M184V challenges assumptions about drug resistance. In resource-limited settings, where genotyping and alternative drug options are unavailable, continuing first-line treatment, reinforcing adherence and regular virologic monitoring may be effective even after virologic failure.

மறுப்பு: இந்த சுருக்கமானது செயற்கை நுண்ணறிவு கருவிகளைப் பயன்படுத்தி மொழிபெயர்க்கப்பட்டது மற்றும் இன்னும் மதிப்பாய்வு செய்யப்படவில்லை அல்லது சரிபார்க்கப்படவில்லை

இந்தக் கட்டுரையைப் பகிரவும்

குறியிடப்பட்டது

arrow_upward arrow_upward